NASDAQ · Biotechnology

RZLT (RZLT) Stock

$4.88 +3.83% NASDAQ: RZLT Healthcare

Valuation

MetricValue
Price$4.88
Market Cap$469.91M
P/E Ratio-3.28
P/B Ratio1.90
P/S Ratio0.00
EPS (TTM)$-0.98
52-Week High$11.46
52-Week Low$1.07
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-45.68%
ROA-42.29%
ROCE-49.38%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio14.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-23.0M$-42.0M$-56.0M$-70.0M$-80.0M
Net Profit$-21.0M$-41.0M$-52.0M$-68.0M$-74.0M
EPS$-2.72$-2.32$-1.01$-1.33$-0.98
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$43.0M$152.0M$124.0M$133.0M$175.0M
Total Liabilities$17.0M$3.0M$8.0M$12.0M$13.0M
Cash$41.0M$150.0M$16.0M$70.0M$94.0M
Borrowings$14.0M$0$2.0M$2.0M$2.0M

Latest News

Rezolute to Participate in the BTIG Virtual Biotechnology Conference GlobeNewswire · Jul 21, 2026 Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society GlobeNewswire · Jun 17, 2026 Exploring 3 High Growth Tech Stocks in US Market Simply Wall St. · Jun 15, 2026 Positive Signs As Multiple Insiders Buy Rezolute Stock Simply Wall St. · Jun 10, 2026 RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? Zacks · Jun 4, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-20.0M$-40.0M$-44.0M$-57.0M$-69.0M
Investing Cash Flow$0$0$-102.0M$49.0M$-15.0M
Financing Cash Flow$-4.0M$31.0M$-1.0M$14.0M$0
Net Cash Flow$31.0M$109.0M$-134.0M$54.0M$24.0M
Free Cash Flow$-20.0M$-40.0M$-45.0M$-57.0M$-69.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-23.55%
Quick Ratio15.84
Interest Coverage—
Return 1Y-9.69%
Return 3Y193.37%
Return 5Y-54.66%

Ownership

Insiders Held10.15%
Institutions Held90.63%
Institutions Float Held100.87%
Institutional HolderSharesReport Date
Blackrock Inc.6,313,5032026-03-31
Opaleye Management Inc.6,300,0002026-03-31
Balyasny Asset Management LP5,048,4212026-03-31
Vanguard Capital Management LLC3,522,0802026-03-31
Jennison Associates LLC3,438,8812026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
DAWNDay One Biopharmaceuticals, Inc. $21.53 +0.00% -20.70 $2.22B 0.00%
EYPT $12.41 +1.80% -4.34 $1.04B 0.00%
GERN $1.34 -4.29% 23.17 $859.64M 0.00%
KURA $9.57 +3.13% -2.90 $849.57M 0.00%
MRVI $6.90 +3.06% -4.48 $1.90B 0.00%

About RZLT

RZLT is led by CEO Nevan Charles Elam, employs 64 people, headquartered in US, publicly traded since 2013.

RZLT stock trades at $4.88 with a market capitalization of $469.91M. The stock is valued at a price-to-earnings (P/E) ratio of -3.28, price-to-book of 1.90, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.07 and $11.46, and currently trades 57.4% below its 52-week high.

On profitability, RZLT generates a return on equity (ROE) of -45.68%, return on capital employed of -49.38%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides